title: Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
authors.forename: C
authors.initials: C
authors.lastname: Enzensberger
authors.forename: K
authors.initials: K
authors.lastname: Eskef
authors.forename: A
authors.initials: A
authors.lastname: Schwarze
authors.forename: D
authors.initials: D
authors.lastname: Faas
authors.forename: R
authors.initials: R
authors.lastname: Axt-Fliedner
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001946:Breech Presentation; D002585:Cesarean Section; D057915:Drug Substitution; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007668:Kidney / Q000187:drug effects; D016104:Oligohydramnios / Q000139:chemically induced / Q000000981:diagnostic imaging; D000068557:Olmesartan Medoxomil; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016216:Ultrasonography, Prenatal
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil